{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:41:37Z","timestamp":1773798097519,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00277-024-05975-7","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T03:35:12Z","timestamp":1725420912000},"page":"4557-4565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed\/refractory multiple myeloma"],"prefix":"10.1007","volume":"103","author":[{"given":"Scott R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Slade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary D.","family":"Crees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Stockerl-Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"5975_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97:1086\u20131107. https:\/\/doi.org\/10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"5975_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjh.18185","volume":"198","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Hungria V, Mohty M, Mateos MV (2022) How I treat triple-class refractory multiple myeloma. Br J Haematol 198:244\u2013256","journal-title":"Br J Haematol"},{"key":"5975_CR3","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V et al (2022) LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 36:1371\u20131376. https:\/\/doi.org\/10.1038\/s41375-022-01531-2","journal-title":"Leukemia"},{"key":"5975_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M et al (2023) PERSEUS: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2312054","journal-title":"N Engl J Med"},{"key":"5975_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-177546","volume":"142","author":"F Gay","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA et al (2023) Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone as Pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood 142:4. https:\/\/doi.org\/10.1182\/blood-2023-177546","journal-title":"Blood"},{"key":"5975_CR6","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J et al (2020) GRIFFIN: Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136:936\u2013945. https:\/\/doi.org\/10.1182\/blood.2020005288","journal-title":"Blood"},{"key":"5975_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00842","author":"T Martin","year":"2022","unstructured":"Martin T, Usmani SZ, Berdeja JG et al (2022) CARTITUDE-1 2YFU: Ciltacabtagene Autoleucel, an Anti\u2013B-cell maturation Antigen chimeric Antigen receptor T-Cell therapy, for Relapsed\/Refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.22.00842","journal-title":"J Clin Oncol"},{"key":"5975_CR8","doi-asserted-by":"publisher","unstructured":"San-Miguel J, Dhakal B, Yong K et al (2023) CARTITUDE-4: Cilta-Cel or Standard Care in Lenalidomide-Refractory multiple myeloma. N Engl J Med 1\u201313. https:\/\/doi.org\/10.1056\/nejmoa2303379","DOI":"10.1056\/nejmoa2303379"},{"key":"5975_CR9","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/nejmoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B et al (2023) KarMMa-3: Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 388:1002\u20131014. https:\/\/doi.org\/10.1056\/nejmoa2213614","journal-title":"N Engl J Med"},{"key":"5975_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/nejmoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N et al (2021) KarMMa: Idecabtagene Vicleucel in Relapsed and Refractory multiple myeloma. N Engl J Med 384:705\u2013716. https:\/\/doi.org\/10.1056\/nejmoa2024850","journal-title":"N Engl J Med"},{"key":"5975_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ et al (2022) MajesTEC-1 P1\/P2: Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387:495\u2013505. https:\/\/doi.org\/10.1056\/nejmoa2203478","journal-title":"N Engl J Med"},{"key":"5975_CR12","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS et al (2023) MagnetisMM-1: Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med 29:2570\u20132576. https:\/\/doi.org\/10.1038\/s41591-023-02589-w","journal-title":"Nat Med"},{"key":"5975_CR13","unstructured":"Firestone RS, Mailankody S Current use of CAR T cells to treat multiple myeloma"},{"key":"5975_CR14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00277-020-03970-2","volume":"99","author":"SR Goldsmith","year":"2020","unstructured":"Goldsmith SR, Fiala MA, Wang B et al (2020) DCEP and bendamustine\/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. Ann Hematol 99:1041\u20131048. https:\/\/doi.org\/10.1007\/s00277-020-03970-2","journal-title":"Ann Hematol"},{"key":"5975_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1358\/dot.2021.57.11.3343690","volume":"57","author":"SR Goldsmith","year":"2021","unstructured":"Goldsmith SR, Liu L, Covut F (2021) Isatuximab for the treatment of multiple myeloma. Drugs Today 57:665\u2013675. https:\/\/doi.org\/10.1358\/dot.2021.57.11.3343690","journal-title":"Drugs Today"},{"key":"5975_CR16","doi-asserted-by":"crossref","unstructured":"Martin TG, Corzo K, Chiron M et al (2019) Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells 8","DOI":"10.3390\/cells8121522"},{"key":"5975_CR17","doi-asserted-by":"crossref","unstructured":"Van De Donk NWCJ, Usmani SZ (2018) CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol 9","DOI":"10.3389\/fimmu.2018.02134"},{"key":"5975_CR18","doi-asserted-by":"crossref","unstructured":"Mikhael J, Belhadj-Merzoug K, Hulin C et al (2021) A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J 11","DOI":"10.1038\/s41408-021-00478-4"},{"key":"5975_CR19","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B et al (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117:4691\u20134695. https:\/\/doi.org\/10.1182\/blood-2010-10-299487","journal-title":"Blood"},{"key":"5975_CR20","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346","journal-title":"Lancet Oncol"},{"key":"5975_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00277-013-1952-5","volume":"93","author":"S Park","year":"2014","unstructured":"Park S, Lee SJ, Jung CW et al (2014) DCEP for relapsed or refractory multiple myeloma after therapy with novel agents. Ann Hematol 93:99\u2013105. https:\/\/doi.org\/10.1007\/s00277-013-1952-5","journal-title":"Ann Hematol"},{"key":"5975_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.clml.2022.12.004","volume":"23","author":"BR Shank","year":"2023","unstructured":"Shank BR, Primeaux B, Yeung EK et al (2023) Hyperfractionated cyclophosphamide and dexamethasone alone or in combination with Daratumumab and\/or Carfilzomib for the treatment of relapsed or refractory multiple myeloma: a single-Center Retrospective Analysis. Clin Lymphoma Myeloma Leuk 23:279\u2013290. https:\/\/doi.org\/10.1016\/j.clml.2022.12.004","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5975_CR23","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1002\/cncr.29533","volume":"121","author":"PT Griffin","year":"2015","unstructured":"Griffin PT, Ho VQ, Fulp W et al (2015) A comparison of salvage infusional chemotherapy regimens for recurrent\/refractory multiple myeloma. Cancer 121:3622\u20133630. https:\/\/doi.org\/10.1002\/cncr.29533","journal-title":"Cancer"},{"key":"5975_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG et al (2022) MonumenTAL-1: Talquetamab, a T-Cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2204591","journal-title":"N Engl J Med"},{"key":"5975_CR25","doi-asserted-by":"crossref","unstructured":"Sidana S, Hosoya H, Jensen A et al (2023) Bendamustine vs. fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer J 13","DOI":"10.1038\/s41408-023-00929-0"},{"key":"5975_CR26","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ajh.27069","volume":"98","author":"SY Ong","year":"2023","unstructured":"Ong SY, Pak S, Mei M et al (2023) Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. Am J Hematol 98:1751\u20131761. https:\/\/doi.org\/10.1002\/ajh.27069","journal-title":"Am J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05975-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05975-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05975-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T01:02:06Z","timestamp":1730768526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05975-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5975"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05975-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to study initiation, this study underwent review by and received approval from the Protocol Review and Monitoring Committee (Siteman Cancer Center) and the Institutional Review Board (Washington University in Saint Louis). All patients provided informed consent at time of study enrollment. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"SRG reports honoraria from Oncovalent, Wugen Inc, Sanofi-Genzyme, Janssen Pharmaceuticals, and Adaptive Biotechnologies and research funding from BMS. MJS reports research support from Secura Bio, Rapid Novor and Pfizer. MF reports no relevant conflicts of interest. MH reports no relevant conflicts of interest. ZDC reports research funding and honoraria from Bioline. MAS reports honoraria from Advarra, Equillium Inc, GSK, Incyte, Inmagene Bio, Novo Nordisk, and StemLine. KSG reports research support from Sanofi. RV reports research support from BMS, Takeda, and Sanofi and honoraria from BMS, Sanofi, Janssen, Pfizer, Regeneron, and Karyopharm.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}